• Mira Pharmaceuticals reported positive results from a 7-day repeated-dose Beagle dog study of SKNY-1, its oral obesity candidate designed to preserve lean body mass.
• The results have already been presented, showing rapid absorption with systemic exposure that rose with dose, supporting confidence in dose selection.
• The findings are intended to de-risk the planned GLP toxicology program, a key step toward IND-enabling development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036262), on August 06, 2026, and is solely responsible for the information contained therein.